Targeted Oncology™ announces the addition of Carolina Blood and Cancer Care to their Strategic Alliance Partnership programs.<br />
Targeted Oncology™, a multimedia resource that offers content and expert opinions on standard and emerging treatments in the oncology field, along with The American Journal of Managed Care® (AJMC®), announces the addition of Carolina Blood and Cancer Care (CBCCA) to their Strategic Alliance Partnership (SAP) programs.
“We are proud to partner with CBCCA,” said Michael J. Hennessy Jr., president of MJH Associates, Inc., parent company of Targeted Oncology™ and AJMC®. “CBCCA helps patients overcome cancer both physically and emotionally, and it is a pleasure to be working with such a great practice.”
With two locations in South Carolina, CBCCA is committed to serving and helping patients overcome cancer. The practice empowers patients to be in control of their treatment and their life while keeping them well informed about their conditions and choices. CBCCA believes in a balanced approach to cancer care physically, emotionally and spiritually.
“The physical effects of cancer on the body is only part of the struggle our patients and their families go through on a daily basis. We have always endeavored to provide care for our patients beyond chemo and biologics regimens. With the advent of site agnostic and mutation specific precision medicine directed treatment, our partnering with Targeted Oncology and AJMC will help us deliver our approach to cancer treatment nationally. We are excited to begin our work,” said Dr. Kashyap Patel, the chief executive of CBCCA as well as the associate editor in chief forAJMC®andEvidence-Based Oncology.
The Targeted Oncology™ SAP program is constantly building a community of advocacy groups, medical associations and medical institutions to foster collaboration and an open exchange of information for the ultimate benefit of patients and their families and to improve patient care. As part of this joint effort, Targeted Oncology™ and AJMC® will work with CBCCA to share exclusive content and educational opportunities.
For more information about the Targeted Oncology™ SAP program, clickhere.
For more information about CBCCA, clickhere.
Differentiating Pseudoprogression From Hyperprogression in Patients Treated With Immunotherapies
Advances in the field have also led to the recognition of other clinical challenges, including unforeseen observations and complications associated with choosing the sequencing of appropriate therapeutic interventions as well as the management of drug-related complications.
Read More
MJH Life Sciences™ Announces Partnership with Global Liver Institute
April 20th 2021The privately-owned health care media company, is excited to officially announce that it has expanded its Strategic Alliance Partnership program with the addition of the Global Liver Institute, a collaborative and innovative platform for the entire spectrum of liver diseases and liver health advocates.
Read More